Table 1.
General characteristics of men with BPH using finasteride or dutasteride
| Dutasteride | Finasteride | |||
|---|---|---|---|---|
| monotherapy | & alpha-blocker | monotherapy | & alpha-blocker | |
| N = 3,147 | N = 8,675 | N = 2,264 | N = 3,517 | |
| n (%) | n (%) | n (%) | n (%) | |
| Age at cohort entry | ||||
| 50–54 years | 150 (5) | 330 (4) | 172 (8) | 148 (4) |
| 55–59 years | 320 (10) | 860 (10) | 255 (11) | 371 (11) |
| 60–64 years | 468 (15) | 1,541 (18) | 341 (15) | 577 (16) |
| 65–79 years | 1,659 (53) | 4,681 (54) | 1,101 (49) | 1,847 (53) |
| 80–84 years | 330 (10) | 848 (10) | 246 (11) | 378 (11) |
| 85–89 years | 169 (5) | 348 (4) | 101 (4) | 151 (4) |
| ≥ 90 | 51 (2) | 67 (1) | 48 (2) | 45 (1) |
| Mean (±SD) | 70 ± 10 | 70 ± 9 | 69 ± 10 | 70 ± 9 |
| Prescriber of first 5-ARI | ||||
| Urologist | 1,705 (54) | 5,053 (58) | 653 (29) | 1,412 (40) |
| GP | 1,063 (34) | 2,242 (26) | 1,275 (56) | 1,546 (44) |
| Other | 379 (12) | 1,380 (16) | 336 (15) | 559 (16) |
| Prior use of urological care | ||||
| Yes | 2,055 (65) | 6,164 (71) | 943 (42) | 1,946 (55) |
| History of bladder or kidney stones | ||||
| Yes | 50 (2) | 148 (2) | 16 (1) | 48 (1) |
| Comorbidities | ||||
| Hypertension | 1,653 (53) | 4,444 (51) | 1,116 (49) | 1,771 (50) |
| Hypercholesterolemia | 1,060 (34) | 2,948 (34) | 662 (29) | 1,094 (31) |
| Diabetes type I | 42 (1) | 113 (1) | 50 (2) | 73 (2) |
| Diabetes type II | 322 (10) | 930 (11) | 209 (9) | 372 (11) |
| Parkinson’s disease | 42 (1) | 148 (2) | 41 (2) | 50 (1) |
| Multiple sclerosis | 1 (<0.5) | 1 (<0.5) | 0 (0) | 2 (<0.5) |
| Chronic disease score | ||||
| 0–3 | 1,402 (45) | 3,987 (46) | 1,137 (50) | 1,634 (46) |
| 4–7 | 939 (30) | 2,516 (29) | 619 (27) | 1,017 (29) |
| ≥ 8 | 806 (26) | 2,172 (25) | 508 (22) | 866 (25) |
| Mean (±SD) | 5 ± 4 | 5 ± 4 | 4 ± 4 | 5 ± 4 |
| Adherence (MPR 5-ARI) (%) | ||||
| Mean (±SD) | 84 ± 13 | 85 ± 13 | 81 ± 14 | 84 ± 13 |
| Database follow-up after cohort entry date | ||||
| ≥ 1 year | 2,264 (100) | 3,517 (100) | 3,147 (100) | 8,675 (100) |
| ≥ 2 years | 1,906 (84) | 2,975 (85) | 2,361 (75) | 6,395 (74) |
| ≥ 3 years | 1,596 (70) | 2,463 (70) | 1,700 (54) | 4,526 (52) |
| ≥ 4 years | 1,291 (57) | 1,991 (57) | 1,115 (35) | 2,972 (34) |
| ≥ 5 years | 970 (43) | 1,490 (42) | 618 (20) | 1,715 (20) |
SD standard deviation, IQR interquartile range, MPR medication possession rate